New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties
about
Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic ApproachesCompstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemiaGenetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis.New milestones ahead in complement-targeted therapy.Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatinNew compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristicsTherapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filtersCompstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole bloodComplement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endotheliumCompstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathyIdentification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics.Applying complement therapeutics to rare diseases.Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.Therapeutic control of complement activation at the level of the central component C3.Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Progress and Trends in Complement TherapeuticsUsing an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40.Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesComplement in immune and inflammatory disorders: therapeutic interventions.Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantationCombined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4-MD2 Complex.Complement inhibition in pre-clinical models of periodontitis and prospects for clinical applicationRational engineering of a minimized immune inhibitor with unique triple-targeting properties.A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsisComplement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.The complement system in inflammatory bowel disease.Inflammaging in skin and other tissues - the roles of complement system and macrophage.Complement component C3 - The "Swiss Army Knife" of innate immunity and host defenseCyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation.Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII.Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.Targeting the complement cascade: novel treatments coming down the pike.
P2860
Q26797414-4384B6A3-EFEE-4F10-A164-294AA77EEE98Q30276082-FD7BAA9C-20FE-4544-902A-E146FB2519C8Q30582298-FB2AB7D3-F87B-47D4-825A-51E5365E4BEFQ33602320-8750F929-833A-4EB6-A483-823CA47A1CC9Q34254555-4E673F48-1832-4C0E-B068-80D1F3DD8AF7Q35013460-8A6D3CF7-66C0-44AA-9411-D79F626BC6DEQ35164180-3A05CE6A-B467-43EF-99E2-7CD194C7DBB4Q35236103-6EA1883B-0115-4AC6-988F-8603EE5B84D4Q35247803-B5935C89-D930-47DD-AAB9-1EF9826A2A5DQ35252156-4CCE87E8-8D07-4E7B-8869-EA0AE4891CD8Q35252177-0671111F-2395-41C1-A140-7DD317243AA1Q35877192-ED5717CA-0A8C-41DE-BF97-010A4EABE4D3Q36309711-EDBBE31B-6B84-486A-AA6F-C445EBB19AD0Q36315497-AE11F487-EE72-4C03-A9FC-C53D22703716Q36338990-314B5D6A-4D2D-40BC-A4AF-CBC6480581B6Q36363005-727D5D65-462A-419D-9BDB-0022A25F86E4Q36460034-71603224-B517-4690-AE84-B4F856E7AFB1Q36463266-FD92E1A9-0F47-4EB0-B9E6-E78C8238DC62Q36479278-98EA2C9B-28D5-4A38-B683-C90DE48FA1B0Q36668896-BC1633E7-F438-4960-B131-0646A0D33898Q36717275-EA39ECD3-7AE0-4F3C-82CE-0C2F33F079C5Q36756690-7B9EF08B-D8EE-4F14-9093-158C2FF0B783Q36756854-87AEB674-DA11-48D7-B95F-22ECEBE775C9Q36945134-635C3253-3C50-40DB-A2B3-72EC30C5DBEDQ37003067-67236643-0FE2-40A9-9612-78500651433DQ37180462-D6003A03-F783-4CFA-9AC4-51822A4A350DQ37300691-88F9FBE9-6BCB-4E37-AED2-3F96B488EA54Q37393792-268F6A2D-5BF6-4DCE-BD60-1DF5F7E3FA04Q37417618-579CFFFF-E3E6-44D0-BE8F-72B0B8BF59B5Q37670073-279D5307-AAD2-4445-969E-DDA89B04481FQ37700323-700289DB-32C0-48C2-88AF-108628514F63Q38042223-A5CFE3C7-E153-41EB-A9F0-CDB97C6C41CAQ38211992-5FAED55F-744F-414E-97E1-E2F3FF644C98Q38213952-B43B1018-15D1-4942-A106-774D8029D49CQ38558926-04B96252-B75A-4130-BD95-BC3A81767580Q38601679-35E98528-CAC9-4215-84B9-F657E773FF93Q38675415-FA28F791-4FA6-4492-82C2-6C74E656BC97Q38762314-DAE1BF1C-9002-4A8D-966A-F10005D4DF7BQ38817075-48D8630C-EBCF-4B85-A5F2-62A564F86C21Q38850489-B878AC46-CD92-4C37-BFA2-1A1D6E8066B0
P2860
New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
New analogs of the clinical co ...... ced pharmacokinetic properties
@ast
New analogs of the clinical co ...... ced pharmacokinetic properties
@en
type
label
New analogs of the clinical co ...... ced pharmacokinetic properties
@ast
New analogs of the clinical co ...... ced pharmacokinetic properties
@en
prefLabel
New analogs of the clinical co ...... ced pharmacokinetic properties
@ast
New analogs of the clinical co ...... ced pharmacokinetic properties
@en
P2093
P2860
P1433
P1476
New analogs of the clinical co ...... ced pharmacokinetic properties
@en
P2093
Apostolia Tzekou
Daniel Ricklin
Edimara S Reis
Florea Lupu
Hongchang Qu
Hongjun Bai
Mateusz Maciejewski
Paul N Barlow
Ranillo R G Resuello
P2860
P304
P356
10.1016/J.IMBIO.2012.06.003
P577
2012-06-17T00:00:00Z